Blockchain Registration Transaction Record

ABVC BioPharma Anticipates $7M Cash Licensing Income in 2025

ABVC BioPharma expects $7M in cash licensing income in 2025 from global agreements signed in 2023, focusing on ophthalmology, CNS, and oncology/hematology. Progress in botanical drug development and plans for utilizing land assets for growth are highlighted, positioning the company in expanding markets for MDD, ADHD, and botanical drugs.

ABVC BioPharma Anticipates $7M Cash Licensing Income in 2025

This news matters as ABVC BioPharma's expected $7M cash licensing income and advancements in botanical drug development signify significant progress in the biopharmaceutical industry. The company's strategic positioning in expanding markets for MDD, ADHD, and botanical drugs highlights its commitment to innovative treatments and addressing unmet medical needs.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x2840a09f14fc24524af260b29708d217c5f66326d689797335e442d7bbde3a8f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintnoteXjd7-8b84d896c55148454c76d37ec7184628